Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Carbone

Showing results (131-140 of 190) with videos related to

Pageof 19
Sort By:
Clinical Reviews in Allergy & Immunology|November 29, 2017
Geoepidemiology of Primary Biliary Cholangitis: Lessons from SwitzerlandBenedetta Terziroli Beretta-Piccoli, Guido Stirnimann, Andreas Cerny, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|August 29, 2017
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicineMarco Carbone, Laura Cristoferi, Paolo Angelo Cortesi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 29, 2019
Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitisLindsey Kennedy, Heather Francis, Pietro Invernizzi, et al.
Journal of Hepatology|March 8, 2013
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohortGreta Pells, George F Mells, Marco Carbone, et al.
Journal of Digestive Diseases|May 22, 2019
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiencyVincenzo Ronca, Qu Bo Chen, Vasiliky Lygoura, et al.
BMJ Open|January 9, 2026
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trialLaura Cristoferi, Daphne D'Amato, Cesare Maino, et al.
Hepatology Communications|May 16, 2018
NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acidKathy L de Graaf, Geneviève Lapeyre, Florence Guilhot, et al.
JHEP Reports : Innovation in Hepatology|October 21, 2022
Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitisDiletta Overi, Guido Carpino, Laura Cristoferi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 21, 2020
Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United KingdomStephen Rice, Viviana Albani, Dimitrios Minos, et al.
Alimentary Pharmacology & Therapeutics|September 22, 2025
Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary CholangitisNadir Abbas, Rachel Smith, Ellina Lytvyak, et al.
Pageof 19

Showing results (131-140 of 190) with videos related to

Sort By:
Pageof 19
Clinical Reviews in Allergy & Immunology|November 29, 2017
Geoepidemiology of Primary Biliary Cholangitis: Lessons from SwitzerlandBenedetta Terziroli Beretta-Piccoli, Guido Stirnimann, Andreas Cerny, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|August 29, 2017
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicineMarco Carbone, Laura Cristoferi, Paolo Angelo Cortesi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 29, 2019
Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitisLindsey Kennedy, Heather Francis, Pietro Invernizzi, et al.
Journal of Hepatology|March 8, 2013
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohortGreta Pells, George F Mells, Marco Carbone, et al.
Journal of Digestive Diseases|May 22, 2019
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiencyVincenzo Ronca, Qu Bo Chen, Vasiliky Lygoura, et al.
BMJ Open|January 9, 2026
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trialLaura Cristoferi, Daphne D'Amato, Cesare Maino, et al.
Hepatology Communications|May 16, 2018
NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acidKathy L de Graaf, Geneviève Lapeyre, Florence Guilhot, et al.
JHEP Reports : Innovation in Hepatology|October 21, 2022
Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitisDiletta Overi, Guido Carpino, Laura Cristoferi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 21, 2020
Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United KingdomStephen Rice, Viviana Albani, Dimitrios Minos, et al.
Alimentary Pharmacology & Therapeutics|September 22, 2025
Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary CholangitisNadir Abbas, Rachel Smith, Ellina Lytvyak, et al.
Pageof 19